Department of Otolaryngology-Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China.
Shandong Provincial Key Laboratory of Otology, Jinan, 250021, China.
Curr Med Sci. 2019 Feb;39(1):52-58. doi: 10.1007/s11596-019-1999-1. Epub 2019 Mar 13.
This work is aimed at exploring the clinical efficacy of continuous positive airway pressure (CPAP) in treatment of patients with arrhythmias combined with obstructive sleep apnea (OSA). Through evaluating serum native thiol, malonaldehyde (MDA) and nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) in these patients and describing the effects on oxidative parameters of CPAP therapy for 3 months, we confirmed the impact of oxidative stress on arrhythmias. A total of 64 patients with OSA combined with arrhythmias were collected from April 2014 to April 2017 with full clinical information. Patients were divided into two groups (paired experiment design): 32 patients in group A (control group), who received unchanged anti-arrhythmia treatment and 32 patients in group B, who were subjected to unchanged pharmacological anti-arrhythmia therapy combined with CPAP. OSA related parameters were compared between the two groups after 3-month therapy. And the levels of parameters of oxidative stress in patients were measured before and after CPAP therapy. After 3 months of CPAP therapy, compared with the control group, the percentage of sage N3 (NREM 3) and stage R (REM) in total sleep time was significantly increased, while apnea-hypopnea index (AHI) and the Epworth Sleepiness Scale (ESS) score were evidently decreased. Meanwhile, the lowest oxygen saturation (LSpO) was also elevated after CPAP treatment for 3 months. The CPAP therapy significantly prevented the occurrence of arrhythmias (P<0.05). Both the MDA level and NADPH oxidase levels were significantly lower in the group B than in the group A (P<0.05). But serum native thiol was improved by CPAP treatment (P<0.05). In conclusion, proper use of CPAP therapy provides significant benefits for the treatment of arrhythmia in patients with OSA.
本研究旨在探讨持续气道正压通气(CPAP)治疗心律失常合并阻塞性睡眠呼吸暂停(OSA)患者的临床疗效。通过评估这些患者的血清天然巯基、丙二醛(MDA)和烟酰胺腺嘌呤二核苷酸磷酸氧化酶(NADPH 氧化酶),并描述 CPAP 治疗 3 个月对氧化参数的影响,我们证实了氧化应激对心律失常的影响。2014 年 4 月至 2017 年 4 月共收集了 64 例 OSA 合并心律失常患者,均有完整的临床资料。患者分为两组(配对实验设计):A 组(对照组)32 例,给予常规抗心律失常治疗;B 组 32 例,在常规抗心律失常药物治疗的基础上联合 CPAP。治疗 3 个月后比较两组患者 OSA 相关参数,并检测两组患者 CPAP 治疗前后氧化应激参数的变化。CPAP 治疗 3 个月后,与对照组相比,B 组患者总睡眠时间中 sage N3(NREM 3)和 R 期(REM)的比例明显增加,而呼吸暂停低通气指数(AHI)和 Epworth 嗜睡量表(ESS)评分明显降低。同时,CPAP 治疗 3 个月后最低血氧饱和度(LSpO)也升高。CPAP 治疗可显著预防心律失常的发生(P<0.05)。与 A 组相比,B 组 MDA 水平和 NADPH 氧化酶水平明显降低(P<0.05),而血清天然巯基则在 CPAP 治疗后得到改善(P<0.05)。结论:合理应用 CPAP 治疗可为 OSA 合并心律失常患者的治疗带来显著获益。